Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Current Leases (2023 - 2025)

Historic Current Leases for China SXT Pharmaceuticals (SXTC) over the last 3 years, with Q3 2025 value amounting to $64118.0.

  • China SXT Pharmaceuticals' Current Leases rose 11090.75% to $64118.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $64118.0, marking a year-over-year increase of 11090.75%. This contributed to the annual value of $61229.0 for FY2025, which is 500.6% up from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Current Leases stood at $64118.0 for Q3 2025, which was up 11090.75% from $61229.0 recorded in Q1 2025.
  • Over the past 5 years, China SXT Pharmaceuticals' Current Leases peaked at $64118.0 during Q3 2025, and registered a low of $30401.0 during Q3 2024.
  • Its 3-year average for Current Leases is $54719.7, with a median of $58199.5 in 2023.
  • In the last 5 years, China SXT Pharmaceuticals' Current Leases crashed by 4587.78% in 2024 and then skyrocketed by 11090.75% in 2025.
  • Quarter analysis of 3 years shows China SXT Pharmaceuticals' Current Leases stood at $56171.0 in 2023, then tumbled by 45.88% to $30401.0 in 2024, then surged by 110.91% to $64118.0 in 2025.
  • Its Current Leases stands at $64118.0 for Q3 2025, versus $61229.0 for Q1 2025 and $30401.0 for Q3 2024.